Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities Publisher Pubmed

Alirezaee A^{1, 2} ; Mirmoghtadaei M^{1, 2} ; Heydarlou H^{1, 2} ; Akbarian A³ ; Alizadeh Z^{1, 2}

Source: Cytokine Published:2025

Abstract

The COVID-19 pandemic has caused significant morbidity and mortality worldwide. The emergence of the Alpha and Delta variants of SARS-CoV-2 has led to a renewed interest in using interferon therapy as a potential treatment option. Interferons are a group of signaling proteins produced by host cells in response to viral infections. They play a critical role in the innate immune response to viral infections by inducing an antiviral state in infected and neighboring cells. Interferon therapy has shown promise as a potential treatment option for COVID-19. In this review paper, we review the current knowledge regarding interferon therapy in the context of the Alpha and Delta variants of SARS-CoV-2 and discuss the challenges that must be overcome to translate laboratory findings into effective clinical treatments. © 2024 Elsevier Ltd

Related Docs

View other Related Docs

1. Human Genetic and Immunological Determinants of Critical Covid-19 Pneumonia, Nature (2022)

2. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)

3. The Role of Type I Interferon in the Treatment of Covid-19, Journal of Medical Virology (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Fazel Shokri (1)

Other Related Docs

4. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)

5. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)

6. Immunoediting in Sars-Cov-2: Mutual Relationship Between the Virus and the Host, International Immunopharmacology (2022)

7. Immune Profiling of Sars-Cov-2; What We Know and What We Don’T Know, Iranian Journal of Allergy# Asthma and Immunology (2023)

8. Potential Therapeutic Applications of Extracellular Vesicles in the Immunopathogenesis of Covid-19, Pathology Research and Practice (2023)

9. Immunology, Immunopathogenesis and Immunotherapeutics of Covid-19; an Overview, International Immunopharmacology (2021)

10. Interferon-Beta Offers Promising Avenues to Covid-19 Treatment: A Systematic Review and Meta-Analysis of Clinical Trial Studies, Naunyn-Schmiedeberg's Archives of Pharmacology (2021)

11. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)

12. Classification of the Present Pharmaceutical Agents Based on the Possible Effective Mechanism on the Covid-19 Infection, DARU# Journal of Pharmaceutical Sciences (2020)

13. The Role of Sars-Cov-2 Accessory Proteins in Immune Evasion, Biomedicine and Pharmacotherapy (2022)

14. An Overview on the Treatments and Prevention Against Covid-19, Virology Journal (2023)

15. Exploration of Blood−Derived Coding and Non-Coding Rna Diagnostic Immunological Panels for Covid-19 Through a Co-Expressed-Based Machine Learning Procedure, Frontiers in Immunology (2022)

16. Molecular Signaling Pathways, Pathophysiological Features in Various Organs, and Treatment Strategies in Sars-Cov2 Infection, Acta Histochemica (2022)

17. Review on Interferon Beta: From Cells to Clinical Usage, Koomesh (2022)

18. Efficacy of Mrna, Adenoviral Vector, and Perfusion Protein Covid-19 Vaccines, Biomedicine and Pharmacotherapy (2022)

19. Covid-19 As a Trigger of Guillain-Barre Syndrome: A Review of the Molecular Mechanism, Immunity# Inflammation and Disease (2023)

20. Immunological Mechanisms of the Nucleocapsid Protein in Covid-19, Scientific Reports (2024)

Style	Citing Format
MLA	Alirezaee A, et al.. "Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities." Cytokine, vol. 186, no. , 2025, pp. -.
APA	Alirezaee A, Mirmoghtadaei M, Heydarlou H, Akbarian A, Alizadeh Z (2025). Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities. Cytokine, 186(), -.
Chicago	Alirezaee A, Mirmoghtadaei M, Heydarlou H, Akbarian A, Alizadeh Z. "Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities." Cytokine 186, no. (2025): -.
Harvard	Alirezaee A et al. (2025) 'Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities', Cytokine, 186(), pp. -.
Vancouver	Alirezaee A, Mirmoghtadaei M, Heydarlou H, Akbarian A, Alizadeh Z. Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities. Cytokine. 2025;186():-.
BibTex	@article{ author = {Alirezaee A and Mirmoghtadaei M and Heydarlou H and Akbarian A and Alizadeh Z}, title = {Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities}, journal = {Cytokine}, volume = {186}, number = {}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Alirezaee A AU - Mirmoghtadaei M AU - Heydarlou H AU - Akbarian A AU - Alizadeh Z TI - Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities JO - Cytokine VL - 186 IS - SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Abstract